Tegaserod Treatment for IBS: A Model of Indirect CostsByDean G. Smith, PhD,Victoria Barghout, MSPH,Kristijan H. Kahler, SMApril 15th 2005
Economic Impact of Irritable Bowel Syndrome: What Does the Future Hold?ByBrooks Cash, MD, FACPApril 15th 2005
Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care PopulationByJudith J. Stephenson, SM,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Joaquim Fernandes, BA,Jane F. Beaulieu, MSN,Samuel Joo, MS,Stephen J. Boccuzzi, PhDApril 15th 2005
Total Costs of IBS: Employer and Managed Care PerspectiveByBrooks Cash, MD, FACP,Sean Sullivan, JD,Victoria Barghout, MSPHApril 15th 2005
Budget Impact of Tegaserod on a Managed Care Organization FormularyByMichael A. Bloom, BA,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Judith Bentkover, PhD,Hannah Kurth, BA,Ian M. Gralnek, MD, MSHS,Brennan M. R. Spiegel, MD, MSHSApril 15th 2005
Impairment in Work Productivity and Health-related Quality of Life in Patients With IBSByBonnie B. Dean, PhD,Daniel Aguilar, MPH,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Feride Frech, MPH,David Groves, PhD,Joshua J. Ofman, MDApril 15th 2005
